Clinical Trials

35 enrolled 10 charts

Carcinoma, Hepatocellular

NCT06109467 2026-02-09

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

36 enrolled

Stomach Neoplasms

NCT03727880 2026-02-04

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

28 enrolled 11 charts

Pancreatic Neoplasms

NCT07176312 2026-02-04

ZANGEA

80 enrolled

Neoplasm Metastasis, Stomach Neoplasms

NCT06682806 2026-02-02

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

6 enrolled

Esophageal Neoplasms, Neoplasm Metastasis

NCT06381154 2026-01-30

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

25 enrolled

Pancreatic Neoplasms

NCT06123338 2026-01-29

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

49 enrolled

Esophageal Neoplasms

NCT03264404 2026-01-27

Azacitidine and Pembrolizumab in Pancreatic Cancer

36 enrolled 11 charts

Pancreatic Neoplasms

NCT03257163 2026-01-20

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

40 enrolled

Stomach Neoplasms

NCT06006923 2026-01-20

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

GastrointestinalOther solid neoplasm

1 enrolled

MSI-H Colorectal Cancer

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03844750 2025-12-31

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

6 enrolled 12 charts

Colorectal Neoplasms

NCT05945823 2025-12-29

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

53 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT06640283 2025-12-24

ANA

GastrointestinalGynecologic

150 enrolled

Anal Canal Carcinoma, Uterine Cervical Neoplasms

NCT04729322 2025-12-23

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

15 enrolled

Colorectal Neoplasms

NCT05998447 2025-12-16

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

10 enrolled

Biliary Tract Neoplasms

NCT04798781 2025-12-11

Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma

16 enrolled 13 charts

Carcinoma, Hepatocellular, Stomach Neoplasms

NCT05131919 2025-12-09

PUMA

25 enrolled

Colorectal Neoplasms

NCT06230471 2025-12-09

Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

60 enrolled

Biliary Tract Neoplasms Immunotherapy

NCT02921256 2025-12-04

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

363 enrolled 16 charts

Rectal Neoplasms

NCT04753879 2025-12-04

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

38 enrolled

Pancreatic Neoplasms

NCT04209686 2025-12-03

Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

36 enrolled

Stomach Neoplasms

NCT06001658 2025-12-03

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

27 enrolled

Biliary Tract Neoplasms, Carcinoma

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT04887805 2025-11-19

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

28 enrolled

Pancreatic Neoplasms

NCT05052723 2025-11-19

Cabozantinib and Pembrolizumab in Metastatic Pancreas

21 enrolled 12 charts

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT03984578 2025-11-18

Window of Opportunity Study in Colorectal Cancer

33 enrolled

Colorectal Neoplasms

NCT04828486 2025-11-18

Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer

14 enrolled 13 charts

Carcinoma, Hepatocellular

NCT03797326 2025-11-17

LEAP-005

BreastCNSGastrointestinalGynecologic

611 enrolled 27 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05256381 2025-11-17

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

GastrointestinalGynecologicThoracic

166 enrolled 43 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Ovarian Neoplasms, Colorectal Neoplasms

NCT07223424 2025-11-10

PSI-Immune